Sangamo BioSciences | SGMO - Debt


Sangamo BioSciences reported $0 in Debt for its fiscal quarter ending in June of 2022.





Debt Change Date
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Amgen USD 54.59B 1.62B Sep/2025
Bayer EUR 39.39B 1.31B Mar/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Cipla INR 4.38B 231.9M Mar/2025
Clal Biotechnology ILS 35.76M 28.27M Dec/2023
Compugen USD 2.95M 24K Sep/2025
CSL USD 11.96B 219M Dec/2024
Gilead Sciences USD 24.94B 5M Sep/2025
GlaxoSmithKline GBP 17.75B 396M Sep/2025
Grifols EUR 9.23B 626.05M Dec/2024
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
J&J USD 47.93B 2.14B Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Merck USD 41.37B 5.97B Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Omeros USD 442.16M 199K Sep/2023
Pfizer USD 60.85B 78M Sep/2025
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025